The University of Chicago Header Logo

Connection

Michael Charlton to Drug Therapy, Combination

This is a "connection" page, showing publications Michael Charlton has written about Drug Therapy, Combination.
Connection Strength

1.094
  1. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation. 2019 04; 103(4):733-746.
    View in: PubMed
    Score: 0.146
  2. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.113
  3. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.112
  4. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
    View in: PubMed
    Score: 0.109
  5. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.107
  6. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.050
  7. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
    View in: PubMed
    Score: 0.046
  8. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.045
  9. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.038
  10. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
    View in: PubMed
    Score: 0.034
  11. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
    View in: PubMed
    Score: 0.034
  12. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
    View in: PubMed
    Score: 0.032
  13. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
    View in: PubMed
    Score: 0.032
  14. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.032
  15. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.031
  16. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.030
  17. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.029
  18. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc. 2014 May; 89(5):595-601.
    View in: PubMed
    Score: 0.026
  19. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.024
  20. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.